Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
View Patent ↗The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.
1. A method for inhibiting Vascular Endothelial Growth Factor-D (VEGF-D) mediated cell growth, migration, or differentiation, comprising administering to a human subject an antibody that specifically binds VEGF-D, wherein the antibody is administered in an amount effective to inhibit VEGF-D interaction with VEGFR-2 or VEGFR-3, and wherein the antibody comprises
a light chain variable region comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain variable region comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 39;
a human antibody light chain constant region; and
a human antibody heavy chain constant region.
2. A method for inhibiting Vascular Endothelial Growth Factor-D (VEGF-D) mediated cell growth, migration, or differentiation, comprising administering to a human subject a chimeric or humanized antibody that specifically binds VEGF-D, wherein the antibody is administered in an amount effective to inhibit VEGF-D interaction with VEGFR-2 or VEGFR-3, and wherein the chimeric or humanized antibody comprises
heavy chain complementarity determining regions from a mouse antibody and framework regions from non-murine source, wherein the heavy chain variable region (VH) comprises complementarity determining regions (CDR) with the amino acid sequences: H-CDR1 set forth in SEQ ID NO: 50, H-CDR2 set forth in SEQ ID NO: 51, and H-CDR3 set forth in SEQ ID NO: 52;
light chain complementarity determining regions from a mouse antibody and framework regions from non-murine source, wherein the light chain variable region (VL) comprises complementarity determining regions (CDR) with the amino acid sequences L-CDR1 set forth in SEQ ID NO: 47, L-CDR2 set forth in SEQ ID NO: 48, and L-CDR3: set forth in SEQ ID NO: 49;
a human antibody light chain constant region; and
a human antibody heavy chain constant region.
3. The method according to claim 2 , wherein the framework regions of the heavy chain variable region and the framework regions of the light chain variable region comprise human framework regions.
4. A method for inhibiting Vascular Endothelial Growth Factor-D (VEGF-D) mediated cell growth, migration, or differentiation, comprising administering to a human subject a chimeric or humanized antibody that specifically binds VEGF-D, wherein the antibody is administered in an amount effective to inhibit VEGF-D interaction with VEGFR-2 or VEGFR-3, and wherein the chimeric or humanized antibody comprises complementarity determining regions (CDR) of non-human origin from SEQ ID NOS: 37 and 39 and constant regions of light and heavy chains, said constant region being of human origin, wherein the biological function of specific binding to said VEGF-D is preserved.